Bajaj Healthcare stock surges 13% as firm inks definitive CDMO pact for 15 APIs with UK/EU customers

Bajaj Healthcare Ltd has announced a significant milestone with the signing of a definitive CDMO agreement with esteemed UK/EU-based customers

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

APIs, intermediates, and formulations manufacturer Bajaj Healthcare Ltd has on February 28 announced signing of a definitive CDMO (Contract Development and Manufacturing Organization) agreement with UK/EU-based customers. This agreement involves the supply of 15 Active Pharmaceutical Ingredients (APIs) to be exclusively manufactured for its clientele.

The firm's stock reacted positively on Wednesday despite a crack in the benchmark indices. At 1325 hours on February 28, Bajaj Healthcare's scrip on BSE was trading 13% higher at Rs 363.2.

The APIs covered in this agreement span a wide range of compounds, including off-patent generics and molecules soon to be off-patent. Bajaj Healthcare will be responsible for the development and supply of these molecules, leveraging its in-house R&D and manufacturing capacities located at Savli Vadodara, Gujarat.

The agreement marks a significant step forward for Bajaj Healthcare as it continues to expand its presence in the global pharmaceutical market and strengthen its foothold in API development and manufacturing.